Cargando…

Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

OBJECTIVES: To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN). METHODS: 453 PMP patients were included from the database at our center. The dataset w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xin, Li, Xinbao, Lin, Yulin, Ma, Ru, Zhang, Ying, Xu, Dazhao, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939117/
https://www.ncbi.nlm.nih.gov/pubmed/36054637
http://dx.doi.org/10.1002/cam4.5138
_version_ 1784890775082893312
author Zhao, Xin
Li, Xinbao
Lin, Yulin
Ma, Ru
Zhang, Ying
Xu, Dazhao
Li, Yan
author_facet Zhao, Xin
Li, Xinbao
Lin, Yulin
Ma, Ru
Zhang, Ying
Xu, Dazhao
Li, Yan
author_sort Zhao, Xin
collection PubMed
description OBJECTIVES: To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN). METHODS: 453 PMP patients were included from the database at our center. The dataset was divided into a training set to establish BN model and a testing set to perform internal validation at a ratio of 8:2. From the training set, univariate and multivariate analyses were performed to identify independent prognostic factors for BN model construction. The confusion matrix, receiver operating characteristic (ROC) curve and the area under curve (AUC) were used to evaluate the performance of the BN model. RESULTS: The univariate and multivariate analyses identified 7 independent prognostic factors: gender, previous operation history, histological grading, lymphatic metastasis, peritoneal cancer index, completeness of cytoreduction and splenectomy (all p < 0.05). Based on independent factors, the BN model of training set was established. After internal validation, the accuracy and AUC of the BN model were 70.3% and 73.5%, respectively. CONCLUSION: The BN model provides a reasonable level of predictive performance for PMP patients undergoing CRS + HIPEC.
format Online
Article
Text
id pubmed-9939117
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99391172023-02-20 Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy Zhao, Xin Li, Xinbao Lin, Yulin Ma, Ru Zhang, Ying Xu, Dazhao Li, Yan Cancer Med RESEARCH ARTICLES OBJECTIVES: To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN). METHODS: 453 PMP patients were included from the database at our center. The dataset was divided into a training set to establish BN model and a testing set to perform internal validation at a ratio of 8:2. From the training set, univariate and multivariate analyses were performed to identify independent prognostic factors for BN model construction. The confusion matrix, receiver operating characteristic (ROC) curve and the area under curve (AUC) were used to evaluate the performance of the BN model. RESULTS: The univariate and multivariate analyses identified 7 independent prognostic factors: gender, previous operation history, histological grading, lymphatic metastasis, peritoneal cancer index, completeness of cytoreduction and splenectomy (all p < 0.05). Based on independent factors, the BN model of training set was established. After internal validation, the accuracy and AUC of the BN model were 70.3% and 73.5%, respectively. CONCLUSION: The BN model provides a reasonable level of predictive performance for PMP patients undergoing CRS + HIPEC. John Wiley and Sons Inc. 2022-08-21 /pmc/articles/PMC9939117/ /pubmed/36054637 http://dx.doi.org/10.1002/cam4.5138 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Zhao, Xin
Li, Xinbao
Lin, Yulin
Ma, Ru
Zhang, Ying
Xu, Dazhao
Li, Yan
Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
title Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
title_full Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
title_fullStr Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
title_full_unstemmed Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
title_short Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
title_sort survival prediction by bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939117/
https://www.ncbi.nlm.nih.gov/pubmed/36054637
http://dx.doi.org/10.1002/cam4.5138
work_keys_str_mv AT zhaoxin survivalpredictionbybayesiannetworkmodelingforpseudomyxomaperitoneiaftercytoreductivesurgeryplushyperthermicintraperitonealchemotherapy
AT lixinbao survivalpredictionbybayesiannetworkmodelingforpseudomyxomaperitoneiaftercytoreductivesurgeryplushyperthermicintraperitonealchemotherapy
AT linyulin survivalpredictionbybayesiannetworkmodelingforpseudomyxomaperitoneiaftercytoreductivesurgeryplushyperthermicintraperitonealchemotherapy
AT maru survivalpredictionbybayesiannetworkmodelingforpseudomyxomaperitoneiaftercytoreductivesurgeryplushyperthermicintraperitonealchemotherapy
AT zhangying survivalpredictionbybayesiannetworkmodelingforpseudomyxomaperitoneiaftercytoreductivesurgeryplushyperthermicintraperitonealchemotherapy
AT xudazhao survivalpredictionbybayesiannetworkmodelingforpseudomyxomaperitoneiaftercytoreductivesurgeryplushyperthermicintraperitonealchemotherapy
AT liyan survivalpredictionbybayesiannetworkmodelingforpseudomyxomaperitoneiaftercytoreductivesurgeryplushyperthermicintraperitonealchemotherapy